CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced
Innovative technology represents a breakthrough scientific achievement for highly contagious respiratory disease
Higher efficacy was observed in mRNA-1283 compared to Spikevax in adults 18 years of age and older
The National One Health Mission will help India to achieve integrated disease control and pandemic preparedness
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
The Institute is catering the health needs of the surrounding population with ever-increasing OPD every year along with special OPDs like mother & Child OPD, and LSD clinic
Receives registration of Valganciclovir powder for oral solution in Germany
The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer
VaxTRIALS Adds a New Latin America Base and Greater Vaccine Research Depth
NIH’s candidate is based on the Adenovirus 4 backbone, largely used as a vector candidate in HIV and influenza vaccine clinical trials
Subscribe To Our Newsletter & Stay Updated
